Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AMPD3 | Q01432 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13477324 | 0.98 | CYP4F2 (0.51) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL10001104 | 0.91 | CYP4F2 (0.45) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL6067652 | 0.84 | MEN1 (0.54) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL7510917 | 0.82 | MEN1 (0.57) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL10631549 | 0.82 | MEN1 (0.57) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL25189076 | 0.82 | MEN1 (0.57) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL7508348 | 0.82 | MEN1 (0.57) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL10031336 | 0.82 | CYP4F2 (0.70) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL14502372 | 0.82 | MEN1 (0.57) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL7508728 | 0.82 | CYP4F2 (0.48) | CYP4F2CYP4A11PKMTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029223-A1 | METHOD FOR PRODUCTION OF SUBSTITUTED ALKYL MALONIC ESTERS AND DERIVATIVES THEREOF | APOSENSE LTD. (IL) | 2012-02-02 | — | — | US | disclosed |
| WO-2012014195-A1 | METHOD FOR PRODUCTION OF SUBSTITUTED ALKYL MALONIC ESTERS AND DERIVATIVES THEREOF | APOSENSE LTD. (IL) | 2012-02-02 | — | — | WO | disclosed |
| US-20110257434-A1 | PERTURBED MEMBRANE-BINDING COMPOUNDS AND METHODS OF USING THE SAME | APOSENSE LTD. (IL) | 2011-10-20 | — | — | US | disclosed |
| US-20110257434-A1 | PERTURBED MEMBRANE-BINDING COMPOUNDS AND METHODS OF USING THE SAME | APOSENSE LTD. (IL) | 2011-10-20 | — | — | US | disclosed |
| US-7947253-B2 | compounds such as 2-methyl-2(3-fluoropropyl)-malonic Acid that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, i.e., cells undergoing cell death, apoptotic cells or activated platelets | APOSENSE LTD. (IL) | 2011-05-24 | — | — | US | disclosed |
| US-7947253-B2 | compounds such as 2-methyl-2(3-fluoropropyl)-malonic Acid that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, i.e., cells undergoing cell death, apoptotic cells or activated platelets | APOSENSE LTD. (IL) | 2011-05-24 | — | — | US | disclosed |
| US-7670590-B2 | Perturbed membrane-binding compounds and methods of using the same | APOSENSE LTD. (IL) | 2010-03-02 | — | — | US | disclosed |
| US-7670590-B2 | Perturbed membrane-binding compounds and methods of using the same | APOSENSE LTD. (IL) | 2010-03-02 | — | — | US | disclosed |
| US-20100035296-A1 | COMPOUNDS AND METHODS FOR DETECTION OF CELLS | APOSENSE LTD. (IL) | 2010-02-11 | — | — | US | disclosed |
| US-20080279774-A1 | Perturbed Membrane-Binding Compounds And Methods Of Using The Same | NST NEUOROSURIVAL TECHNOLOGIES LTD. (IL) | 2008-11-13 | — | — | US | disclosed |
| US-20080279774-A1 | Perturbed Membrane-Binding Compounds And Methods Of Using The Same | NST NEUOROSURIVAL TECHNOLOGIES LTD. (IL) | 2008-11-13 | — | — | US | disclosed |
| WO-2008081447-A2 | COMPOUNDS AND METHODS FOR DETECTION OF CELLS | APOSENSE LTD. (IL) | 2008-07-10 | — | — | WO | disclosed |
| US-20080014148-A1 | Perturbed membrane-binding compounds and methods of using the same | APOSENSE LTD. (IL) | 2008-01-17 | — | — | US | disclosed |
| US-20080014148-A1 | Perturbed membrane-binding compounds and methods of using the same | APOSENSE LTD. (IL) | 2008-01-17 | — | — | US | disclosed |
| US-7270799-B2 | Perturbed membrane-binding compounds and methods of using the same | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2007-09-18 | — | — | US | disclosed |
| US-7270799-B2 | Perturbed membrane-binding compounds and methods of using the same | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035296-A1 | COMPOUNDS AND METHODS FOR DETECTION OF CELLS | CASP3, BAX, BAD | CYP4F2 3199/4885CYP4A11 2901/4885PKM 1410/4885 |
| US-20120029223-A1 | METHOD FOR PRODUCTION OF SUBSTITUTED ALKYL MALONIC ESTERS AND DERIVATIVES THEREOF | ME1, MAL2, ME3 | CYP4F2 854/4885CYP4A11 866/4885PKM 555/4885 |
| US-20110257434-A1 | PERTURBED MEMBRANE-BINDING COMPOUNDS AND METHODS OF USING THE SAME | ANXA5, SELPLG, ANXA6 | CYP4F2 4506/4885CYP4A11 4794/4885PKM 2112/4885 |
| US-20080014148-A1 | Perturbed membrane-binding compounds and methods of using the same | ANXA5, SELPLG, ANXA6 | CYP4F2 4224/4885CYP4A11 4638/4885PKM 2161/4885 |
| US-20080279774-A1 | Perturbed Membrane-Binding Compounds And Methods Of Using The Same | ANXA5, SELPLG, ANXA6 | CYP4F2 4224/4885CYP4A11 4638/4885PKM 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.